Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 127 of 127 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1038.

    Technology appraisal guidance
    Published
    3 November 2021

  2. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  4. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  5. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

    HealthTech guidance
    Published
    17 April 2025
    View recommendations

    Sections for HTG742

  6. Past appeals and decisions

    Past technology appraisal appeals and decisions

  7. Cost saving guidance

    reduction in surgical interventions. Capacity savings: £5,100 Guideline on thyroid disease: assessment and management (NG145) Savings...